Nebivolol in heart failure teatment

Heart failure represents the final point of many cardiovascular disorders and has a prevalence of around 1-2% in the general population, rising to >10% in individuals aged 70 years. Advances in pharmacological and intracardiac device-based therapies have reduced mortality rates in patients with HF, but both short-and long-term mortality rates remain significant. Heart failure remains as 'malignant' as some of the common cancers in both men and women. Beta-blockers have been one of the mainstays of treatment with ensuing prognostic and symptomatic benefits, and different societies have thus included them in guidelines for management of heart failure. However, controversy exists as to the optimal selection of a particular beta-blocker for management of heart failure, as the available beta-blockers differ in their selectivity for adrenergic receptors and their effects on the peripheral circulation. Nebivolol is a third-generation, long-acting and highly selective 1 adrenoreceptor antagonist that also exhibits nitric oxide-mediated vasodilatory effects via 3 receptor agonism. Patients who develop a chronic heart failure usually need lifelong treatment, and finding the optimal personalized treatment for every patient is crucial. Management of heart failure should be based on the presence and magnitude of cardiovascular, noncardiovascular systems and comorbid conditions as well as on the individual characteristics of the drugs especially beta-blockers in question.